



SciFinderⁿ hakkında özet bilgi:

SciFinderⁿ programını geliştiren Chemical Abstracts Service (CAS), American Chemical Society (ACS)'nin bir birimidir, dünyadaki en geniş kimya ve kimya ile ilgili literatür veritabanına sahiptir.

SciFinderⁿ özellikle Kimya ve İlaç firmaları, Kimya ve Kimya ile ilgili bölümler; Biyoloji, Fizik, Eczacılık, Tıp, Kimya Mühendisliği, Çevre Mühendisliği, Gıda Mühendisliği, Polimer Mühendisliği, Malzeme ve Metalürji Mühendisliği, Farmakoloji, Nanoteknoloji, Tekstil Mühendisliği, Enerji Sistemleri Mühendisliği, Biyomedikal Mühendisliği, Ziraat Mühendisliği, Jeoloji Mühendisliği vb. bölümlerin kullanabilecekleri önemli bir programdır.

SciFinderⁿ içeriğinde bulunan veritabanları;

CAPLUS (Referans Kaynaklar) | **CAS REGISTRY** (Kimyasallar) | **CASREACT** (Kimyasal Reaksiyonlar)

MARPAT (Markush Kimyasalları) | **CHEMLIST** (Kimyasal Regülasyon) | **CHEMCATS** (Kimyasal Sağlayıcı Katalogları)

CAPLUS (Referans Kaynaklar)

Kimya ve kimya ile ilgili alanlardaki araştırma kaydı içerir, bu kayıtlar **makale, patent konferans bildirileri, sempozyum, kitap, teknik rapor ve doktora tezlerini** içermekte, 1907'den günümüze kadar olan literatürü kapsamaktadır.

10500'ün üzerinde fen bilimleri ile ilgili **akademik dergiyi** taramaktadır. Toplamda günümüze kadar **50000**'den fazla dergi indekslenmiştir.

63 patent ofisinden gelen patentler taranabilmektedir. **PatentPak** modülü sayesinde patentler çok daha kolay incelenebilmektedir.

İçerik indeksleri, bilim adamları tarafından oluşturulmuştur. İngilizce dışında farklı dillerde yazılmış (50'den fazla dil) makale özetleri, İngilizce'ye çevrilerek sunulmaktadır.

Citation Map özelliği eklenmiştir.

CAS REGISTRY (Kimyasallar) & **CASREACT** (Kimyasal Reaksiyonlar)

170 milyon üzeri **organik ve anorganik madde**

127 milyon üzeri **kimyasal reaksiyon**

68 milyon üzeri **protein ve nükleik asit dizisi (sequences)**


7,6 milyar üzeri **kimyasal özellik bilgisi**

108 milyondan fazla H- ve C- NMR spectra arşivi bünyesinde bulundurup, bunları tarama olanağı sağlamaktadır.


SciFinderⁿ ile kimyasal ve reaksiyonların çizimi yapılarak ilgili literatür bilgilerine ulaşılabilir.

Retrosentez özelliği ile deneysel ve tahmini retrosentez planlaması yapılabilir.

SciFinderⁿ arama arayüzü;



Referansların gösterimi;



Referansa tıklandığında gelen detaylar;

Go to References screen.

Retrieve data for reference.

Access an interactive version of the patent PDF that highlights the specific location of indexed substances.

View previous or next reference.

Access map of references this document cites, and references that cite this document.

Download, email, or save reference.

Access other full-text options.

PDF displays original patent PDF.
PDF+ displays patent PDF with table of important chemistry.
Viewer displays interactive version of PDF in PatentPak Viewer.

Click to view patent family member on Reference Detail screen.

Expand to view concepts that characterize the general subject matter of the document.

Expand to view substances associated with document.

Expand to view citations from this document.

Patent Information

Patent Number: WO2015058034

Publication Date: 2015-04-23

Application Number: WO2014-US61038

Application Date: 2014-10-17

Kind Code: A1

Assignee: The Regents of the University of Colorado, A Body Corporate, United States

Source: World Intellectual Property Organization

Database Information: AN: 2015:690500, CAN: 162:544597, CAPlus

Language: English

Abstract: The invention provides methods for reducing apoptosis of non-cancerous cells during a cancer treatment and beneficial effects associated with reducing such apoptosis. In particular, methods of the invention comprise administering a tyrosine kinase inhibitor to a cancer patient who is undergoing cancer treatment in order to reduce apoptosis of non-cancerous cells. In another aspect of the invention the tyrosine kinase inhibitor is selected from the group consisting of dasatinib, imatinib, ponatinib, saracatinib, and a combination thereof.

Figure A: Timeline of treatment and sampling. Timeline shows 0 hr, 1 hr, 4 hr, 30 Days, 60 Days, and 90 Days. Treatments include +TKI, +IR, and +TKI. Sampling points are Collect Saliva at 30 Days, 60 Days, and 90 Days.

Figure B: Bar chart showing Saliva Flow / Weight (Y-axis, 0 to 2.5) versus Days Following Radiation (X-axis: 0, 63, 90). Legend: Control (black), Dasatinib (grey), IR (white), IR + Dasatinib (light grey). Data shows a significant decrease in saliva flow/weight for the IR group compared to Control and Dasatinib groups at 63 and 90 days.

Figure C: Bar chart showing Saliva Flow / Weight (Y-axis, 0 to 2.5) versus Days Following Radiation (X-axis: 0, 60). Legend: Control (black), Imatinib (grey), IR (white), IR + Imatinib (light grey). Data shows a significant decrease in saliva flow/weight for the IR group compared to Control and Imatinib groups at 60 days.

Figure D: Bar chart showing Saliva Flow / Weight (Y-axis, 0 to 2.5) versus Days Following Radiation (X-axis: 0, 30). Legend: Control (black), Bosutinib (grey), IR (white), IR + Bosutinib (light grey). Data shows a significant decrease in saliva flow/weight for the IR group compared to Control and Bosutinib groups at 30 days.

Patent Family Table:

Patent	Language	Kind Code	PatentPak Options	Publication Date	Application Number	Application Date
WO2015058034	English	A1	PDF PDF+ Viewer	2015-04-23	WO2014-US61038	2014-10-17
P					US2013-61893132P	2013-10-18
US20160228436	English	A1	PDF	2016-08-11	US2016-1515029617	2016-04-14

Substances (12)

Substance Role: Pharmacological Activity (7)

Substance 1: 943319-70-8, C20H27F7N5O, Benzamide, 3-[2-imidazo[1,2-b]pyridazin-3-ylethynyl]-, **PatentPak**

Substance 2: 380843-75-4, C20H24Cl2N6O3, 3-Quinolinesulfonylcarbamoyl, 4-[[2,4-dichloro-5-methoxy-1,3,5-triazin-2-yl]amino]-, **PatentPak**

Substance 3: 379231-04-6, C20H24ClN6O3, 4-Quinolinesulfonylcarbamoyl, 4-[[2,4-dichloro-5-methoxy-1,3,5-triazin-2-yl]amino]-, **PatentPak**

Substance Role: Therapeutic Use (7)

Kimyasallarla ilgili arayüz;

The image shows the SciFinder web interface with several callouts highlighting key features:

- Retrieve data related to answers.** Points to the 'Substances (6)' header.
- Download answers to an external file.** Points to the download icon (floppy disk) in the top right.
- Change how answers are displayed.** Points to the 'View Full' dropdown menu.
- Select type of structure match.** Points to the 'Substructure (6)' option under 'Structure Match'.
- Select filters to focus answers.** Points to the 'Filter by' section on the left sidebar.
- Share answers by emailing link.** Points to the email icon in the top right.
- Save answers.** Points to the 'Save' button (star icon) in the top right.
- Retrieve data for substance.** Points to the 'View Detail' link for a specific substance.
- Go to Substance Detail screen.** Points to the 'View Detail' link for a specific substance.
- View Key Physical Properties on Substance Detail screen.** Points to the 'Key Physical Properties' table on the substance detail page.

Substances (6)

References Reactions Suppliers

1219937-98-0
View Detail

C11H9ClFNO2
Cyclopropanecarbonyl chloride, 1-[[[4-fluorophenyl]amino]carbonyl]-

29 References 98 Reactions 1 Supplier

Key Physical Properties	Value	Condition
Molecular Weight	276.09	-
Boiling Point (Predicted)	404.4±30.0 °C	Press: 760 Torr
Density (Predicted)	1.504±0.06 g/cm ³	Temp: 20 °C; Press: 760 Torr
pKa (Predicted)	13.86±0.70	Most Acidic Temp: 25 °C

1416321-38-4
View Detail

C11H8Cl2FNO2
Cyclopropanecarbonyl chloride, 1-[[[3-chloro-4-fluorophenyl]amino]carbonyl]-

1 Reference 2 Reactions 0 Suppliers

Key Physical Properties	Value	Condition
Molecular Weight	276.09	-
Boiling Point (Predicted)	428.6±45.0 °C	Press: 760 Torr
Density (Predicted)	1.600±0.06 g/cm ³	Temp: 20 °C; Press: 760 Torr
pKa (Predicted)	13.18±0.70	Most Acidic Temp: 25 °C

Reaksiyonlarla ilgili arayüz;

Go to Reactions screen.

View previous or next reaction.

Return to All Reaction Schemes

Reaction Detail (Scheme 1, Reaction 2 of 20)

Download answers to an external file.

Share answers by emailing link.

Save data.

Steps: 1

Save

Click any substance image or name to display substance menu. Use menu options to view substance details (CAS Registry Number), zoom image (magnifier), retrieve associated information (Reactions, Suppliers, References), or copy substance to editor (Edit Substance).

Suppliers (2)

Suppliers (25)

Suppliers (55)

Retrieve suppliers for substance.

View reaction reference on Reference Detail screen.

Step 1

Alternative Steps (19)

Stage	Reagents	Catalysts	Solvents	Conditions
1	Potassium carbonate	-	Tetrahydrofuran Water	10 min, > 30 °C
2	Water	-	-	10 h, 15 - 30 °C

CAS Reaction Number 31-365-CAS-4160897

Notes
alternative reaction conditions shown

Experimental Protocols

Experimental Procedure

Preparation of N-(4-((6,7-bis(methyloxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide The solution from the previous step containing 1-(4-fluoro-phenyl)carbonyl-cyclopropanecarbonyl chloride was added to a mixture of 4-(6,7-dimethoxy-quinoline-4-yl)oxyphenylamine (3.0 kg), and potassium carbonate (4.0 kg) in THF (27.0 kg), and water (13.0 kg) at a rate such that the hatch temperature did not exceed 3.0 °C. When the reaction was complete (approximately 10 minutes), water (74.0 kg) was added. The mixture was stirred at 15 to 300 °C for approximately 10 hours, which resulted in the precipitation of the product.. The product was recovered by filtration, washed with a pre made solution of THF (11.0 kg) and water (24.0 kg), and dried at approximately 659 °C under vacuum for approximately 12 hours to afford the title compound. Yield (free base, 5.0 kg). ¹H NMR (400 MHz, d₆-DMSO): δ 10.2 (s, 1 H), 10.05 (s, 1 H), 8.4 (s, 1 H), 7.8 (m, 2H), 7.65 (m, 2H), 7.5 (s, 1H), 7.35 (s, 1H), 7.25 (m, 2H), 7.15 (m, 2H), 6.4 (s, 1H), 4.0 (d, 6H), 1.5 (s, 4H) LC/MS: M-H = 502.

Reference
Method of treating cancer and bone cancer pain
View Reference Detail
By: Schwab, Gisela; et al
World Intellectual Property Organization, WO2012151326 A1
2012-11-08

PATENTPAK Full Text

Patent Information
Patent Number
WO2012151326

Publication
2012-11-08

Application Number
WO2012-US36191

Application Date
2012-05-02


Kind Code
A1

Assignee
Exelixis, Inc., United States

View full-text PDF for the patent reference or Patent Family members.

Access other full-text options.

Retrosentez ile ilgili arayüz;



Geçmiş aramalar ile ilgili arayüz;

Search history

SciFinder[®]
A CAS SOLUTION

References Enter a query...

Draw

Search

Saved Searches

Filter by

Search Type

- ☐ All (23)
- ☐ Substances (542)
- ☐ Reactions (258)
- ☒ Retrosynthesis (9)
- ☒ References (850)
- ☐ Suppliers (27)

Date

Start Date End Date

mm/dd/yyyy to mm/dd/yyyy

April, 2018

SU	MO	TU	WE	TH	FR	SA
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	1	2	3	4	5

Search History (859)



April 25, 2018

- ☐ 5:19 PM
References: theory of relativity (1.5M) [Rerun Search](#)

April 24, 2018

- ☐ 4:36 PM
References: Advanced Search (745)
Author: Laird, E. [Rerun Search](#)

April 19, 2018

- ☐ 1:25 PM
Retrosynthesis:  Synthetic Depth: 3, Rules Supporting Predictions: Uncommon, Break & Protect Bonds: No [Open Plan](#) [Complete](#)
- ☐ 1:20 PM
Retrosynthesis:  Synthetic Depth: 4, Rules Supporting Predictions: Uncommon, Break & Protect Bonds: No [Open Plan](#) [Complete](#)

Citation Map

Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine

By: Pankhania, Mahendra Govind; Yurdakul, Saruhan
 World Intellectual Property Organization, WO9834612
 A1 1998-08-13 | Language: English, Database: Capius
[View Reference Detail](#)

Abstract: Migraine is treated by administering to the patient a pharmaceutical composition containing a therapeutically effective amount of ibuprofen or a salt thereof and a therapeutically effective amount of domperidone or a salt thereof. A pharmaceutical tablet contained ibuprofen 60, domperidone 1.5, tricalcium phosphate 18.50, microcrystalline cellulose 5.9, PVP 3.9, croscarmellose sodium 9.6, and stearic acid 0.6%.

PATENTPAK ▾

Full Text ▾

Filter by

Document Type

☐ Journal (1)
 ☐ Patent (8)
 ☐ Clinical Trial (1)

Author

☐ Highton, Frederick Raymond (2)
 ☐ Rhoades, Tracey Jane (2)
 ☐ Sherry, Robert Arthur (2)
 ☐ Brunelle, Alan (1)
 ☐ Dickinson, Jeffrey (1)

View All

Concept

☐ Pharmaceutical tablets (7)
 ☐ Nonsteroidal anti-inflammatory agents (3)
 ☐ Pharmaceutical capsules (3)
 ☐ Pharmaceutical granules (3)
 ☐ Analgesics (2)

View All

References This Document Cites

Domperidone and NSAIDS for the treatment of migraine

No Source data available (1997)

Cited By 3

Tablet formulations for migraine treatment

No Source data available (1991)

Cited By 3

The role of a peripheral dopamine-antagonist (Motilium) in improving the tolerance to steroidal and non-steroidal anti-inflammatory agents.

Therapia Hungarica (English edition) (1990)

Cited By 1

References Citing This Document

Medicinal compositions comprising a core and a film based on modified cellulose derivatives

No Source data available (2004)

Citing 4

Compressed tablet formulation comprising non-steroidal anti-inflammatory drugs and methods

No Source data available (2012)

Citing 1

Ibuprofen tablet formation with additives such as silicon dioxide and cellulose

No Source data available (2008)

Citing 0

Compressed tablets comprising granular component containing NSAIDS

No Source data available (2001)

Citing 0

Pharmaceutical combination of ibuprofen lysine and domperidone for treating migraine

No Source data available (2000)

Citing 0

Pharmaceutical compositions comprising ibuprofen and domperidone

No Source data available (2000)

Citing 0

Only citations that have reference detail records will appear.